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Abstract 
We present a 20-year-old primiparous patient 
status post heart transplant at 6 months with 
long-standing hypertension progressing to 
super-imposed preeclampsia. Pregnancy and 
delivery after thoracic transplantation is no 
longer a rare occurrence, however, these 
women are at a greater risk of gestational 
hypertension and preeclampsia.1 Current 
literature does not provide treatment guidelines 
for treatment of hypertensive disorders in 
patients with a transplanted heart. In this case 
report, we explore the different treatments for 
maintaining blood pressures in the transplanted 
neurovascular system, effects of eclampsia 
prevention on blood pressure, and how 
fluctuations in blood pressure in a long-standing 
hypertensive can affect fetal heart tracings. A 
literature search was conducted using terms 
“solid organ transplant and preeclampsia”, “Anti-
hypertensive drugs post heart transplant”, and 
“hypertension after heart transplantation”. No 
reviews on treatment of preeclampsia in cardiac 
transplant recipients were evident. 
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Introduction 
Our patient is a 20‐year‐old female with 
a history of hypoplastic left heart status 
post cardiac transplant at 6 months of 
age. She was originally maintained on 
cyclosporine as the primary 
immunosuppressive medication. This 
medication is well known to cause 
kidney issues and hypertension. She 
was diagnosed with hypertension shortly 
after her transplant and was started on 
an ACE inhibitor. The patient has never 
had any acute or chronic rejection 
episodes. Within a few years of 
transplant, she developed Epstein‐Barr 
Virus (EBV) associated Post‐Transplant 
Lymphoproliferative Disease (PTLD) 
and her cyclosporine was stopped 
around age 5. She was started on 
CellCept as her only 
immunosuppressive medication after 
clearance of the PTLD. Prior to 
pregnancy, her hypertension was easily 
managed on enalapril 10mg and 
immunosuppression on mycophenolic 
acid 500mg. 
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Case Report 
The patient presented for prenatal care 
and pregnancy was confirmed at 6 
weeks gestational age. She was not 
using contraception, and the pregnancy 
was unplanned but desired. At that time, 
her medications were adjusted; the 
enalapril and mycophenolic acid were 
discontinued and she was started on 
nifedipine 30mg daily and tacrolimus 
4mg BID with a goal tacrolimus level of 
4‐8. Because CellCept is a teratogen, 
this was switched to low dose tacrolimus 
when it was discovered she was 
pregnant. Heart transplant patients are 
at higher risk for rejection both during 
and after pregnancy.1 The patient was 
also advised to start taking aspirin 81mg 
for preeclampsia precautions due to her 
longstanding hypertension and elevated 
risk due to transplantation.2  Baseline 
labs were obtained and as follows: 
Creatinine 0.8, Platelets 236, AST/ALT 
18/14, 24‐hour urine protein 95 mg. 
Maternal echocardiograms were 
scheduled during the first and third 
trimesters to evaluate cardiac function 
throughout the pregnancy.3 These were 
normal and showed no change from 
baseline ejection fraction. Fetal echo 
was performed at 20 weeks gestation 
due to maternal history increasing the 
risk for fetal cardiac malformations. It 
was normal. 
From the beginning of the pregnancy, 
this patient required multidisciplinary 
care. The Maternal Fetal Medicine 
department held a care conference 
concerning the complexities of her 
treatment. 
Physicians and other healthcare 
workers from pediatric cardiology, 
anesthesia, and the cardiovascular ICU 
department were involved. The main 
medical goals were a vaginal delivery 
with adequate pain control and blood 
pressure stabilization. 
At 36‐weeks and 4‐days gestation, the 
patient presented to clinic for a routine 
prenatal visit. She was complaining of 
feeling unwell and reported a headache, 
but she attributed this to a sinus 
infection. She reported some higher 
blood pressures of 150/80 mmHg earlier 
in the week. Her initial mechanical blood 
pressure was 152/88 mmHg, which was 
then rechecked twice manually and 
found to be 146/93 mmHg and 146/100 
mmHg. She was admitted to Labor and 
Delivery for concern of super‐imposed 
preeclampsia. HELLP labs were 
collected and as follows: Creatinine 1.2, 
Platelets 267, AST/ALT 24/13, and 24‐
hour urine protein 2220 mg. 
The patient was induced for 
superimposed preeclampsia with severe 
features due to blood pressure criteria. 
Initially, induction began with Foley bulb 
placement. After it fell out, Misoprostol 
25 mcg was administered twice for 
cervical ripening. Oxytocin was titrated 
up to 15 cc/hr overnight. Patient had 
spontaneous rupture of membranes, 
and oxytocin was discontinued due to 
late decelerations. Vaginal deliveries are 
recommended in transplant patients 
unless cesarean is otherwise indicated.4 
Adequate pain control is a concern due 
to the effect of pain on blood pressure 
and cardiovascular stress. An epidural 
of bupivacaine 0.1%‐fentanyl 2 mcg at 
12mL/hr was placed at the start of 
induction and was titrated to 14 cc/hr for 
adequate anesthesia. SBE prophylaxis 
was initiated with 2g IV Ampicillin every 
6 hours throughout induction and labor. 
The patient’s blood pressure remained 
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elevated throughout the beginning of 
labor induction, ranging from 131‐
169/58‐99 mmHg. The nifedipine dose 
was increased to 30 mg twice daily and 
administered. 
Systolic blood pressures continued to be 
elevated above 165 mmHg, and IV 
hydralazine 5mg was administered. IV 
magnesium is used for maternal seizure 
prophylaxis with the potentially 
beneficial side effect of lowering blood 
pressure through vasodilation.5 
Magnesium sulfate at 50 cc/hr was 
administered. Overnight, the patient’s 
blood pressure dropped to a range of 
100s/50s mmHg, with a creatinine of 1.6 
and fetal heart decelerations to 80 bpm. 
With the labiality of the patient’s blood 
pressure and late decelerations, the IV 
magnesium infusion was discontinued. 
A central line was placed and the patient 
was started on epinephrine 16 mcg/mL 
infusion. The epinephrine dosage was 
titrated to 22.6 mL/hr with minimal blood 
pressure improvement to 111/58 mmHg. 
Norepinephrine 16 mcg/mL infusion was 
started and the patient’s blood pressure 
returned to 150s/80s after titration up to 
2.3 mL/hr. Fetal heart tracings returned 
to a normal baseline of 140 bpm. 
The infant was born via spontaneous 
vaginal delivery 24 hours after induction 
of labor began. Weight was 2.85 
kilograms and Apgar scores at 1 and 5 
minutes were 9 and 9. No blood gas. 
There were no complications and 
disposition was to the newborn nursery. 
Maternal blood pressures continued to 
be elevated in the range of 150/90 
mmHg, and PO nifedipine 30mg BID 
was prescribed. Blood pressure was 
maintained at 135‐155/80‐90 mmHg. 
The patient was discharged 3 days after 
delivery. 
Three months post‐delivery and the 
patient's blood pressure had stabilized 
at 129/67 mmHg, and nifedipine dose 
has decreased to 30mg daily under 
pediatric cardiologists 
recommendations. There has been no 
sign of transplant rejection. Mirena IUD 
was placed at 6‐week postpartum visit. 
Discussion 
The delivery of a transplant patient is no 
longer a rare event. Along with the 
typical concerns of rejection, 
hypertension and preeclampsia are 
prevalent and a challenge to treat in 
allogeneic cardiac transplants. The 
labiality of this patient’s blood pressure 
was a main concern, as hypertension is 
undesirable, but her sudden 
hypotension was the likely cause of fetal 
distress and acute kidney injury. The 
cause of this patient’s hypotension is 
likely linked to the IV magnesium that 
was used as seizure prophylaxis. She 
was also administered nifedipine, a 
calcium channel blocker. It has been 
hypothesized that calcium channel 
blockers and magnesium can have 
compounding effects.6 Nifedipine can 
also potentiate the toxic effects of IV 
magnesium. It is advised to be aware of 
the effects of magnesium and weigh the 
benefits of seizure prophylaxis against 
relative hypotension in a chronically 
hypertensive patient. These effects on 
the peripheral vascular system most 
likely led to the patient’s hypotension. 
Norepinephrine has greater effect on 
alpha receptors and was the more 
effective pressor in this patient. It was 
advised that beta‐blockers would be 
ineffective on the transplanted 
vasculature, so hydralazine was used 
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for a fast acting hypertensive agent.7 
Norepinephrine appears to be the more 
effective alpha sympathetic agonist for 
blood pressure management in this 
patient’s transplanted neuromuscular 
system, as blood pressure increases 
were minimal on epinephrine. 
Management likely was further 
complicated by the fact that heart 
transplant patients no longer have 
nervous control of the heart, as those 
nerves are severed during the transplant 
process. The transplanted heart rate 
depends on circulating catecholamines; 
there is no vagal control. 
Recommendations include use of 
hydralazine for immediate blood 
pressure control for preeclamptic 
patients with allogenic cardiac 
transplants. Nifedipine is appropriate for 
chronic hypertension in these patients 
during pregnancy. These patients need 
intra‐arterial blood pressure monitoring 
to maintain tight control of blood 
pressure and heart rate. IV magnesium 
for neuroprotection is standard of care, 
but it is imperative to have the support 
to administer pressors if the patient 
becomes hypotensive. Norepinephrine 
is superior to epinephrine in cardiac 
transplant patients. 
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